Allarity Therapeutics

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the upcoming annual meeting of stockholders scheduled on July 26, 2024.

Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares

HUMBOLDT, Tenn.--(BUSINESS WIRE)--Reinhausen Manufacturing Inc. (RM), a subsidiary of Germany-based Maschinenfabrik Reinhausen, is thrilled to announce the official ribbon cutting of its newly expanded manufacturing facility in Humboldt, Tennessee. The ceremony marks the completion of a significant project aimed at enhancing RM's production capabilities and supporting the growing demand for innovative energy solutions across North America. Since breaking ground on the expansion earlier this yea.

Reinhausen Manufacturing Inc Celebrates Ribbon Cutting for Plant Expansion in Humboldt

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 22, 2024, Allarity disclosed that it had received a Wells Notice from the U.S. Securities and Exchange Commission relating to the Company's statements regar.

The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors

Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity's Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company's progress in 2024 and future objectives. Led by New Management Allarity has Materially Strengthened its Finances The Company's overall financial situation significantly improved as the Company today announced a new, strong cash balance and pausing of At-The-Market (ATM) offering:                                New Strong Cash Balance: Allarity Therapeutics is pleased to announce that the Company now has a financial runway extending into 2026 at its current burn rate with a cash balance of $20M as of July 19, 2024.

Allarity Therapeutics Outlines Company's 2024 Progress and Objectives

Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it received notice from the NASDAQ Stock Market (“NASDAQ”) that it was granted a hearing before a Nasdaq Hearings Panel (the “Panel”).

Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it has received formal written notice from The Nasdaq Stock Market, LLC's Office of General Counsel (“Nasdaq”) that the Company has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).

Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended March 31, 2024. "The start of 2024 has been a pivotal period for Allarity Therapeutics, marked by significant achievements across financial, regulatory, and clinical areas," remarked Thomas Jensen, CEO of Allarity Therapeutics.

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

Allarity Therapeutics, Inc. (ALLR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy

- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its capital structure has been simplified. This was achieved by the recent investor-initiated conversion of all outstanding Series A Preferred Stock into common stock, resulting in a single class of shares outstanding, and the conversion of 93% of the Company's outstanding warrants, including all variable-priced warrants.

Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock

- Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq

Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1

Allarity Therapeutics (NASDAQ: ALLR ) stock is rocketing higher on Thursday after the clinical-stage biopharmaceutical company shared results from a Phase 2 clinical trial. Allarity Therapeutics announced the early conclusion of its Phase 2 study of stenoparib as a treatment for advanced recurrent ovarian cancer.

Why Is Allarity Therapeutics (ALLR) Stock Up 39% Today?

Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity's unique Drug Response predictor (DRP®) companion diagnostic (CDx) in order to treat only patients with the highest likelihood of deriving clinical benefit.

Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer

Boston (April 17, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics (NASDAQ: ALLR ) stock is heading higher on Friday alongside heavy pre-market trading. Investors will note that this movement comes after the company announced a prospectus supplement.

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

Boston (April 4, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company's common stock will begin trading on a split-adjusted basis when the market opens on April 9, 2024. This strategic move aims to regain compliance with the Nasdaq's minimum bid price requirement, alongside achieving other operational benefits. The CUSIP number for the Company's common stock following the Reverse Stock Split will be 016744401.

Allarity Therapeutics Announces 1-for-20 Reverse Stock Split

The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA ® and dovitinib is de-prioritized The Company has been able to reduce costs materially Boston (March 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel PARP/Tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its DRP® platform to identify and enroll only the patients most likely to derive clinical benefit. This decision is the outcome of an extensive analysis of the Company's strategic opportunities, initiated immediately after Thomas Jensen stepped into his role as Interim CEO in early December 2023.

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Boston (March 8, 2024) — Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update.

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.

Allarity Therapeutics to Present at Biomarkers 2024

Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition in its leadership. Effective immediately, James G. Cullem is no longer President and CEO. The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer. The Company has also engaged Jeremy R. Graff, Ph.D., as an Executive Advisor. Dr. Graff will work closely with Mr. Jensen and the Board to provide consulting and advisory services on Allarity's research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer.

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer.

Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?

Boston (December 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable disease.

Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic

BOSTON , October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity's development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx.

Allarity Therapeutics to Present at Biomarkers Europe 2023

CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer therapies coupled with companion diagnostics. The company's unique approach involves utilizing its proprietary Drug Response Predictor (DRP®) technology to identify which patients will most likely respond to a specific drug treatment.

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology

- T he DRP ® -Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment , as compared to unselected patients

News for Allarity Therapeutics Stock (ALLR)